Insight Molecular Diagnostics Inc. (IMDX) — Financial statements
Income statement, balance sheet, and cash flow for Insight Molecular Diagnostics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 4↑115.6% | 2↑25.1% | 2↑56.9% | 0.96↓56.4% | 2 | |
| Cost of Revenue | 4↑238.7% | 1↑4.7% | 1↑11.7% | 0.98↑25.4% | 0.78 | |
| Gross Profit | 0.19↓74.3% | 0.74↑79.2% | 0.41↑2394.4% | -0.02↓101.3% | 1 | |
| Operating Expenses | ||||||
| R&D Expenses | 16↑61.6% | 10↑5.9% | 9↑27.3% | 7↑45.0% | 5 | |
| General & Administrative Expenses | 11↓19.1% | 13↑1.3% | 13↓39.7% | 22↑5.5% | 20 | |
| Selling & Marketing Expenses | 6↑889.5% | 0.64↑108.8% | 0.31↑1705.9% | 0.02↑240.0% | 0.01 | |
| SG&A Expenses | 17↑23.1% | 14↑3.8% | 13↓38.3% | 22↑5.6% | 20 | |
| Other Expenses | -2↓105.5% | 38↑1184.7% | 3↑127.4% | -11↓136.5% | 30 | |
| Operating Expenses | 31↓50.2% | 62↑141.8% | 26↑42.1% | 18↓67.4% | 55 | |
| Total Costs & Expenses | 35↓45.0% | 63↑136.2% | 27↑40.5% | 19↓66.1% | 56 | |
| Operating Results | ||||||
| Operating Income | -31↑49.9% | -61↓142.8% | -25↓39.7% | -18↑66.5% | -54 | |
| Depreciation & Amortization | 2↑40.5% | 2↓6.9% | 2↓67.8% | 5↑24.1% | 4 | |
| EBITDA | -28↑51.9% | -59↓155.2% | -23↓73.7% | -13↑72.5% | -48 | |
| EBIT | -31↑49.5% | -61↓144.2% | -25↓33.9% | -19↑64.8% | -53 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.11↓29.8% | -0.08↓61.5% | -0.05↑37.3% | -0.08↑60.3% | -0.21 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.11↑29.8% | 0.08↑61.5% | 0.05↓37.3% | 0.08↓60.3% | 0.21 | |
| Non-Operating Income | 0.00↑100.0% | -0.46↓38.7% | -0.33↓162.6% | 0.53↑150.0% | -1 | |
| Other Income / Expenses | -20↓5296.8% | 0.38↑34.5% | 0.28↑145.7% | -0.62↓172.0% | 0.85 | |
| Income Before Tax | -50↑17.2% | -61↓144.1% | -25↓33.5% | -19↑64.8% | -53 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -9 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -50↑17.2% | -61↓144.1% | -25↓33.5% | -19↑57.3% | -44 | |
| Net Income from Discontinued Operations | 0.00 | 0.00↑100.0% | -3↑94.6% | -54↓165.0% | -20 | |
| Net Income | -50↑17.2% | -61↓118.4% | -28↑61.9% | -73↓13.7% | -64 | |
| Bottom-Line Net Income | -50↑17.6% | -61↓112.1% | -29↑60.9% | -73↓14.5% | -64 | |
| EPS (Basic) | -1.65↑64.6% | -4.66↓24.3% | -3.75↑81.3% | -20.00↓38.9% | -14.40 | |
| EPS (Diluted) | -1.65↑64.6% | -4.66↓24.3% | -3.75↑81.3% | -20.00↓38.9% | -14.40 | |
| Weighted Average Shares | 30↑133.2% | 13↑70.8% | 8↑38.1% | 6↑24.6% | 4 | |
| Weighted Average Diluted Shares | 30↑133.2% | 13↑70.8% | 8↑38.1% | 6↑24.6% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.